Overcoming Resistance Of Human Metastatic Melanoma To Treatment
Funder
National Health and Medical Research Council
Funding Amount
$727,758.00
Summary
Melanoma is a major Australian health problem, but there is no curative treatment once the disease spreads beyond the skin. I have been working on “overcoming resistance of melanoma to treatment” continuously for 10 years. My past research has provided a number of insights into the resistance of melanoma to treatment. I wish to extend my work to find new treatment approaches against the disease. If successful, this work will greatly benefit melanoma patients and Australian people.
Characterisation Of The Role Of Mesenchymal Phenotypes And EGFR In Treatment-resistant Melanoma.
Funder
National Health and Medical Research Council
Funding Amount
$113,237.00
Summary
Phenotypic change has been identified in multiple settings relating to melanoma progression and metastasis. We have identified a degree of overlap between features of phenotypic plasticity, epithelial-to-mesenchymal transition, and the emergence of treatment resistance. This project will further examine mechanisms underlying these changes, focusing on the role of the epidermal growth factor.
Towards Better Treatments For Acral Melanoma Through Functional Genomics
Funder
National Health and Medical Research Council
Funding Amount
$1,456,823.00
Summary
Acral melanoma is an uncommon melanoma subtype with bad prognosis that has been poorly characterised at the molecular level. The project will conduct comprehensive analysis of acral melanoma at the DNA, RNA and protein levels. Through subsequent functional follow-up studies of key drivers of this cancer type we will identify novel drug targets to treat this disease.
Identification Of The Molecular Hallmarks Of Naevi Progressing To Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Melanomas are amongst the most commonly occurring cancers in Australia with >136,000 people living with a previous melanoma diagnosis. One of the highest risk factors for developing melanoma is having a high number of moles (or naevi). It is therefore important to fully understand how and why naevi develop into melanoma. It is hoped that early detection markers will be identified which will help identify early melanomas and as such improve patient outcome.
Delineating Mechanisms Of Acquired Resistance To Kinase Inhibitors And Devising Novel Strategies To Combat Therapeutic Resistance
Funder
National Health and Medical Research Council
Funding Amount
$437,034.00
Summary
Kinase inhibitors are some of the most successful anti-cancer agents that have emerged in the last 15 years. However, tumors become resistant to these drugs after showing initial response. Understanding mechanisms through which cancer cells become resistant to these drugs will allow us to develop effective strategies to counter it and achieve sustained responses to cancer therapy. I propose to build a research program to systematically study these mechanisms to improve cancer therapeutics.
Clinicopathological Characterisation Of Male Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Male Breast Cancer is an uncommon and poorly understood disease. Due to its low frequency, there is a paucity of studies with large numbers of patients. Our aim will be to establish one of the largest worldwide databases of Male Breast Cancer. This will allow us to more thoroughly investigate clinical, pathological and molecular characteristics of male breast cancer, improve treatment of these patients and potentially develop novel and innovative strategies for treatment of female breast cancer.
Companion Biomarker And Therapeutic Strategy Development For Pancreatic Cancer
Funder
National Health and Medical Research Council
Funding Amount
$121,031.00
Summary
Innovation of predictive and responsive biomarkers in pancreatic cancer (PC) is of paramount importance. This project contains two parts: 1. Circulating DNA. It has been shown previously that DNA released into the blood stream by cancer can be measured, its usefulness in PC will be assessed. 2. ROCK-I as a predictive biomarker. ROCK-I is a protein involved in cell motility. The ability for ROCK-I amplification to predict for response to ROCK-I inhibitors will be assessed in vitro/in vivo.
Functional Characterisation Of A New Surface Adhesion Molecule On Human Vascular Progenitor Cells To Combat Cancer
Funder
National Health and Medical Research Council
Funding Amount
$593,794.00
Summary
Collectively, diseases of the blood vascular system contribute immensely to the burden of health care in Australia. Notably, abnormal blood vessel formation is a major cause or contributor to many diseases, such as cancer, cardiovascular disease, rheumatoid arthritis, ischemia injury and diabetes. This project aims to understand the underlying mechanisms associated with aberrant angiogenesis such that it may aid in the identification of novel targets for the development of therapeutics.
Toll-like Receptor 2 Signalling As A Potential Therapeutic Target In Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$323,091.00
Summary
Stomach cancer is the fourth most deadly cancer in the world. Stomach cancer is closely linked with inflammation, and we have shown that a key inflammatory molecule, called toll-like receptor 2 (TLR2), can drive the development of stomach cancer. However, this occurs in a non-inflammatory manner. My research aims to understand how TLR2 is involved in the progression of stomach cancer, with the ultimate goal to find an early biomarker of disease, and to develop better therapies.
Tailoring Targeted Therapy To DNA Repair-defective High-Grade Serous Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$802,247.00
Summary
Ovarian cancer is a major cause of cancer death in women because current treatments are inadequate. Half of aggressive ovarian cancers have abnormalities in DNA repair and should be susceptible to new PARP inhibitor therapy, yet not all those respond. By developing a new model of studying human ovarian cancers in mice, we can discover markers to predict which ovarian cancers will respond best to these exciting new treatments.